New hope for kids with severe colitis: drug trial shows promise

NCT ID NCT05784246

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 34 times

Summary

This study tested a drug called mirikizumab in 63 children aged 2 to 17 with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal was to see if the drug can help control the disease and improve symptoms over 52 weeks. Participants had already tried other treatments without success. The results will help doctors understand if mirikizumab is a safe and effective option for managing this chronic condition in children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

Roma, 00161, Italy
Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer

Florence, 50139, Italy
Centrum Medyczne Oporow

Wroclaw, 52-416, Poland
Children's Center for Digestive Health Care, LLC

Atlanta, Georgia, 30342, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Gabinet Lekarski Bartosz Korczowski

Rzeszów, 35-302, Poland
Hadassah University Hospital, Ein Kerem

Jerusalem, 911200, Israel
Helios Klinikum Wuppertal

Wuppertal, 42283, Germany
Hôpital Necker - Enfants Malades

Paris, 75015, France
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Institute of Science Tokyo Hospital

Bunkyō City, 113-8519, Japan
Instytut 'Pomnik - Centrum Zdrowia Dziecka

Warsaw, 04-730, Poland
Juntendo University Hospital

Bunkyō City, 113-8431, Japan
King Fahad Medical City

Rishon LeZiyyon, 70300, Israel
Kokikai Tsujinaka Hospital Kashiwanoha

Kashiwa-shi, 277-0871, Japan
Kyungpook National University Chilgok Hospital

Daegu, 41404, South Korea
LMU-Campus Innenstadt

München, 80337, Germany
Medical Network Spółka z o. o., WIP Warsaw IBD Point Profesor Kierkus

Warsaw, 04-501, Poland
National Center for Child Health and Development

Setagaya-ku, 157-8535, Japan
Riley Childrens Hospital

Indianapolis, Indiana, 46202, United States
Saga University Hospital

Saga, 849-8501, Japan
Samsung Medical Center

Seoul, 06351, South Korea
Schneider Children's Medical Center

Petah Tikva, 4920235, Israel
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Shaare Zedek

Jerusalem, 9103102, Israel
Sheffield Children's Hospital

Sheffield, S102TH, United Kingdom
The Hospital for Sick Children

Toronto, M5G 0A4, Canada
Twoja Przychodnia-Szczecińskie Centrum Medyczne

Szczecin, 71-434, Poland
UZ Leuven

Leuven, 3000, Belgium
UZA

Edegem, 2650, Belgium
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, 55131, Germany
University of California, San Francisco

San Francisco, California, 94158, United States
Washington University

St Louis, Missouri, 63110-1010, United States
Yokohama City University Medical Center, Center of IBD

Yokohama, 232-0024, Japan

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS ULCERATIVE COLITIS